Novozymes A/S B (NVZMF) - Total Liabilities

Latest total liabilities as of June 2025: $5.66 Billion USD

Based on the latest financial reports, Novozymes A/S B (NVZMF) has total liabilities worth $5.66 Billion USD as of June 2025.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Novozymes A/S B - Total Liabilities Trend (2002–2024)

This chart illustrates how Novozymes A/S B's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Novozymes A/S B Competitors by Total Liabilities

The table below lists competitors of Novozymes A/S B ranked by their total liabilities.

Liability Composition Analysis (2002–2024)

This chart breaks down Novozymes A/S B's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Novozymes A/S B's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Novozymes A/S B (2002–2024)

The table below shows the annual total liabilities of Novozymes A/S B from 2002 to 2024.